A 3-day-old male neonate born to non-consanguineous parents presents with poor feeding, lethargy, and vomiting. On examination, he is hypotonic with a weak cry. Serum ammonia is 280 µmol/L (normal <50 µmol/L). Plasma amino acid analysis shows elevated glutamine and alanine. Urine orotic acid is markedly elevated. What is the most appropriate immediate next step in management?

Explanation

## Clinical Diagnosis This neonate presents with **neonatal hyperammonemia** with the classic triad of poor feeding, lethargy, and vomiting. The elevated plasma glutamine and alanine (which accumulate when ammonia is high) combined with **markedly elevated urine orotic acid** is pathognomonic for **Ornithine Transcarbamylase (OTC) deficiency**, the most common urea cycle disorder. **Key Point:** OTC deficiency causes accumulation of carbamoyl phosphate, which is shunted into the pyrimidine synthesis pathway, producing excess orotic acid in urine. ## Immediate Management Strategy In acute hyperammonemia (especially neonatal presentation with ammonia >200 µmol/L), the priority is **rapid ammonia reduction** to prevent neurological damage and cerebral edema. ### Why Sodium Benzoate and Sodium Phenylbutyrate? 1. **Sodium benzoate**: Conjugates with glycine to form hippurate, which is excreted in urine. This removes 1 nitrogen atom per molecule of benzoate. 2. **Sodium phenylbutyrate**: Converted to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine, excreted in urine. This removes 2 nitrogen atoms per molecule (via glutamine). **High-Yield:** These agents provide **alternative pathways for nitrogen excretion**, bypassing the defective urea cycle. They are the first-line pharmacological treatment in acute hyperammonemia and should be started **immediately** (within hours of diagnosis) to prevent hyperammonemic encephalopathy and death. **Clinical Pearl:** In neonatal OTC deficiency, ammonia levels >200 µmol/L carry risk of irreversible neurological damage. IV administration of these agents can reduce ammonia by 30–50% within 24 hours. ### Supportive Measures (concurrent with above) - Restrict dietary protein (switch to low-protein formula or parenteral nutrition with minimal protein) - Maintain adequate calories with carbohydrate/lipid supplementation - Monitor ammonia levels every 4–6 hours initially ## Why Other Options Are Incorrect or Delayed | Option | Why Not First-Line | |--------|-------------------| | Liver biopsy | Invasive; does not reduce ammonia acutely. Diagnosis is already clinically clear (elevated orotic acid = OTC deficiency). Biopsy may be considered later for confirmation but delays life-saving treatment. | | Hemodialysis | Reserved for ammonia >400–500 µmol/L or when pharmacological measures fail. Not first-line because benzoate/phenylbutyrate are faster and less invasive. May be used as adjunct in severe cases. | | Vitamin B12 | No role in urea cycle disorders. B12 is relevant only in methylmalonic acidemia or homocystinuria. | **Warning:** Delay in starting benzoate/phenylbutyrate in neonatal hyperammonemia can result in permanent neurological sequelae (developmental delay, seizures, coma, death). [cite:Harrison 21e Ch 356]